FDA approves sNDA for Furoscix (furosemide-subcutaneous) to expand the indication to include treatment of edema in patients with chronic kidney disease – sc Pharma
scPharmaceuticals Inc., announced that the FDA has approved the supplemental New Drug Application (sNDA) for Furoscix to expand the indication to include treatment of edema in patients with… read more.